Top Markets
#1 Velas Velas +367.72%
#2 Gravity Gravity +48.70%
#3 Galxe Galxe +41.28%
#4 Infinity Ground Infinity Ground +30.80%
#5 Wiki Cat Wiki Cat +26.84%
#6 Audiera Audiera +26.57%
#7 Fetch.ai Fetch.ai +26.24%
#8 Derive Derive +24.86%
#9 Aria.AI Aria.AI +20.75%
#10 Babylon Babylon +18.83%
Coin of the day
Velas Velas
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Clasificación en acciones #96
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Precio por acción
$38.41
Capitalización bursátil
$170.67B
Cambio (1 día)
1.17%
Cambio (1 año)
-49.92%
País
DK
Comercio Novo Nordisk A/S (NVO)

Categoría

Healthcare
Capitalización bursátil
Ingresos
más
Ganancias
Historial de precios
Ratio P/E
Ratio P/S
Ratio P/B
Margen operativo
EPS
Split de acciones
Dividendos
Rendimiento del dividendo
Acciones en circulación
Ganancias de Novo Nordisk A/S (NVO)
Ganancias en Dec 2025 TTM: $20.51B
Secondo gli ultimi rapporti finanziari di Novo Nordisk A/S, gli utili attuali della società sono $20.51B. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Novo Nordisk A/S desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -77.36%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -74.49%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -89.57%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -92.13%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -92.92%
NL